Crossmark Global Holdings Inc. Sells 2,530 Shares of DaVita Inc. (NYSE:DVA)

Crossmark Global Holdings Inc. lessened its stake in DaVita Inc. (NYSE:DVAGet Rating) by 29.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,119 shares of the company’s stock after selling 2,530 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $507,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of DVA. Lazard Asset Management LLC lifted its holdings in shares of DaVita by 62,708.2% in the second quarter. Lazard Asset Management LLC now owns 687,750 shares of the company’s stock valued at $54,991,000 after purchasing an additional 686,655 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in shares of DaVita by 266.1% in the first quarter. Hsbc Holdings PLC now owns 239,223 shares of the company’s stock valued at $27,193,000 after purchasing an additional 173,878 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of DaVita by 180.8% in the third quarter. Jennison Associates LLC now owns 262,579 shares of the company’s stock valued at $21,734,000 after purchasing an additional 169,065 shares in the last quarter. Bridgewater Associates LP lifted its holdings in shares of DaVita by 117.4% in the second quarter. Bridgewater Associates LP now owns 257,825 shares of the company’s stock valued at $20,616,000 after purchasing an additional 139,248 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of DaVita by 33.9% in the second quarter. FMR LLC now owns 448,485 shares of the company’s stock valued at $35,861,000 after purchasing an additional 113,634 shares in the last quarter. Institutional investors own 86.52% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on DVA. StockNews.com raised DaVita from a “hold” rating to a “buy” rating in a research report on Friday, December 9th. TheStreet downgraded DaVita from a “b-” rating to a “c+” rating in a research report on Tuesday, November 1st. Deutsche Bank Aktiengesellschaft downgraded DaVita from a “buy” rating to a “hold” rating and decreased their price target for the company from $97.00 to $72.00 in a research report on Tuesday, November 1st. UBS Group downgraded DaVita from a “buy” rating to a “neutral” rating and decreased their price target for the company from $117.00 to $74.00 in a research report on Monday, October 31st. Finally, Barclays decreased their price target on DaVita from $103.00 to $81.00 and set an “equal weight” rating for the company in a research report on Monday, October 31st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $81.17.

Insider Activity

In related news, Director John M. Nehra purchased 5,000 shares of DaVita stock in a transaction dated Tuesday, November 1st. The stock was bought at an average cost of $71.14 per share, for a total transaction of $355,700.00. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at $1,067,100. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.00% of the stock is owned by company insiders.

DaVita Stock Performance

NYSE:DVA opened at $80.32 on Monday. The company has a debt-to-equity ratio of 12.63, a current ratio of 1.26 and a quick ratio of 1.22. The business has a fifty day simple moving average of $74.65 and a two-hundred day simple moving average of $82.20. DaVita Inc. has a 1 year low of $65.28 and a 1 year high of $124.81. The company has a market capitalization of $7.24 billion, a P/E ratio of 11.76, a P/E/G ratio of 1.47 and a beta of 0.96.

DaVita (NYSE:DVAGet Rating) last announced its quarterly earnings results on Friday, October 28th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.20). The company had revenue of $2.95 billion during the quarter, compared to analysts’ expectations of $2.98 billion. DaVita had a net margin of 5.84% and a return on equity of 85.60%. DaVita’s revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.36 earnings per share. On average, analysts expect that DaVita Inc. will post 6.32 earnings per share for the current year.

DaVita Company Profile

(Get Rating)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Articles

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.